Live price temporarily unavailable.
Price history
Precision BioSciences (DTIL) is a Health Care company in the Russell 2000. Latest news and coverage below.
IPO: March 28, 2019 · $16.00 offering · NASDAQ · View IPO details →
Precision BioSciences revenue & net income history (FY2018–FY2025)
RevenueNet income
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.9M | $1.07B | $24.3M | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M |
| Growth (year over year) | — | +9731.8% | −97.7% | +375.7% | −78.3% | +94.1% | +41.0% | −50.1% |
| Operating income | −$47.9M | −$87.2M | −$109.8M | −$39.4M | −$62.3M | −$43.7M | −$26.2M | −$52.1M |
| Operating margin | −440.2% | −8.1% | −452.2% | −34.1% | −248.3% | −89.8% | −38.1% | −152.2% |
| Net income | −$46.0M | −$92.9M | −$109.0M | −$30.6M | −$111.6M | −$61.3M | $7.17M | −$45.7M |
| Net margin | −423.0% | −8.7% | −448.9% | −26.5% | −444.8% | −125.8% | 10.4% | −133.4% |
| EPS (diluted) | −$2628.00 | −$1989.00 | −$1881.00 | −$15.60 | −$38.10 | −$15.96 | $1.04 | −$3.56 |
| Balance sheet | ||||||||
| Cash and equivalents | $103.2M | $180.9M | $89.8M | $143.7M | $189.6M | $116.7M | $85.9M | $110.8M |
| Total assets | $138.6M | $235.2M | $150.2M | $211.5M | $238.2M | $159.8M | $136.4M | $154.4M |
| Total liabilities | $98.6M | $96.9M | $105.7M | $120.3M | $177.7M | $140.9M | $80.0M | $62.2M |
| Long-term debt | — | — | — | $2.48M | $22.2M | — | — | — |
| Shareholders' equity | $40.0M | $138.3M | $44.4M | $91.2M | $60.4M | $18.9M | $56.4M | $92.2M |
| Cash flow | ||||||||
| Operating cash flow | −$51.7M | −$71.0M | −$87.4M | −$10.9M | −$45.8M | −$84.1M | −$58.4M | −$65.8M |
| Capital expenditure | $14.3M | $24.7M | $5.03M | $5.05M | $3.32M | $1.96M | $250.0K | $85.0K |
| Free cash flow | −$66.0M | −$95.7M | −$92.4M | −$15.9M | −$49.1M | −$86.1M | −$58.7M | −$65.9M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $576.0K | — | $29.0K | $18.0K | $13.0K | — | $10.8M | $0 |
| Growth (year over year) | −95.6% | — | −99.8% | −100.0% | −97.7% | — | +37272.4% | −100.0% |
| Operating income | −$21.3M | — | −$22.1M | −$21.9M | −$20.7M | — | −$9.07M | −$19.2M |
| Operating margin | −3693.6% | — | −76248.3% | −121538.9% | −158976.9% | — | −83.7% | — |
| Net income | −$16.4M | — | −$20.6M | −$23.5M | −$21.8M | — | −$18.4M | −$32.7M |
| Net margin | −2851.6% | — | −70913.8% | −130666.7% | −167476.9% | — | −170.2% | — |
| EPS (diluted) | −$2.25 | — | −$2.21 | −$2.13 | −$1.84 | — | −$0.75 | −$1.26 |
| Balance sheet | ||||||||
| Cash and equivalents | $98.8M | $85.9M | $77.2M | $62.2M | $44.9M | $110.8M | $99.4M | $86.1M |
| Total assets | $153.3M | $136.4M | $124.4M | $108.9M | $93.5M | $154.4M | $143.9M | $125.9M |
| Total liabilities | $88.4M | $80.0M | $75.1M | $74.9M | $76.9M | $62.2M | $67.8M | $80.6M |
| Shareholders' equity | $64.9M | $56.4M | $49.3M | $34.1M | $16.6M | $92.2M | $76.1M | $45.3M |
| Cash flow | ||||||||
| Operating cash flow | −$5.91M | — | −$19.1M | −$20.3M | −$15.3M | — | −$11.9M | −$13.4M |
| Capital expenditure | $39.0K | — | $64.0K | $2.00K | $0 | — | $18.0K | $0 |
| Free cash flow | −$5.95M | — | −$19.1M | −$20.3M | −$15.3M | — | −$12.0M | −$13.4M |
From Precision BioSciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
About Precision BioSciences
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
Source: Wikipedia — Precision BioSciences
- Headquarters
- Durham, North Carolina From SEC filings, Oct 2026
Recent News
No recent news mentioning Precision BioSciences in our feed yet.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International